From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

So Shiny Object Syndrome is coming home to roost there. … in this weird middle place professionally, where they’re not tech-shiny but they don’t yet often control the purse strings ...

Breakthrough Australian research in the diagnosis of chronic fatigue syndrome is bringing hope to thousands of people living with debilitating exhaustion and pain that can take years to identify.

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...

The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...

But Walz absolutely has caught a case of “main character” syndrome. He seems to have convinced himself that he is a major player. That the Democratic party is clamoring for what he is selling.

‘Princess Syndrome’ - a term used to describe a mindset of entitlement, dependency, and unrealistic expectations - can significantly impact personal and professional growth. It wouldn’t be an ...

Disease name: Trimethylaminuria (TMAU), also known as "fish odor syndrome" Affected populations: TMAU is a rare metabolic condition that causes a person to smell like rotten fish. The condition is ...

Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.

March 27, 2025 – The FDA has approved a drug to treat a key symptom of a rare life-threatening genetic disorder known as Prader-Willi syndrome (PWS) in adults and children ages 4 or older.

The FDA has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets to treat hyperphagia in individuals aged four years and older with Prader-Willi syndrome (PWS). The ...

for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.